MDAI vs. BSGM, TLSI, INGN, ELMD, PROF, KRMD, CVRX, LNSR, AVR, and PDEX
Should you be buying Spectral AI stock or one of its competitors? The main competitors of Spectral AI include Biosig Technologies (BSGM), TriSalus Life Sciences (TLSI), Inogen (INGN), Electromed (ELMD), Profound Medical (PROF), KORU Medical Systems (KRMD), CVRx (CVRX), LENSAR (LNSR), Anteris Technologies Global (AVR), and Pro-Dex (PDEX). These companies are all part of the "medical equipment" industry.
Spectral AI vs. Its Competitors
Spectral AI (NASDAQ:MDAI) and Biosig Technologies (NASDAQ:BSGM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends.
Biosig Technologies has lower revenue, but higher earnings than Spectral AI.
Biosig Technologies has a net margin of 0.00% compared to Spectral AI's net margin of -30.75%. Spectral AI's return on equity of 0.00% beat Biosig Technologies' return on equity.
67.1% of Spectral AI shares are held by institutional investors. Comparatively, 7.2% of Biosig Technologies shares are held by institutional investors. 30.7% of Spectral AI shares are held by company insiders. Comparatively, 17.0% of Biosig Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Spectral AI had 5 more articles in the media than Biosig Technologies. MarketBeat recorded 7 mentions for Spectral AI and 2 mentions for Biosig Technologies. Spectral AI's average media sentiment score of 0.52 beat Biosig Technologies' score of 0.00 indicating that Spectral AI is being referred to more favorably in the media.
Spectral AI has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500. Comparatively, Biosig Technologies has a beta of 1.71, indicating that its share price is 71% more volatile than the S&P 500.
Spectral AI currently has a consensus target price of $4.75, indicating a potential upside of 74.63%. Biosig Technologies has a consensus target price of $10.00, indicating a potential downside of 13.42%. Given Spectral AI's stronger consensus rating and higher probable upside, equities research analysts plainly believe Spectral AI is more favorable than Biosig Technologies.
Summary
Spectral AI beats Biosig Technologies on 11 of the 15 factors compared between the two stocks.
Get Spectral AI News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDAI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MDAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Spectral AI Competitors List
Related Companies and Tools
This page (NASDAQ:MDAI) was last updated on 7/8/2025 by MarketBeat.com Staff
